Core Insights - Adagio Medical Holdings, Inc. is participating in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 10, 2026, in Snowbird, UT [1] - The company specializes in catheter ablation technologies for treating cardiac arrhythmias, focusing on its proprietary Ultra-Low Temperature Cardiac (ULTA) ablation technology [1] - Adagio's vCLAS™ Cryoablation System is currently under evaluation in the FULCRUM-VT U.S. Pivotal IDE Trial, which has fully enrolled 209 patients [1] - The results from the FULCRUM-VT trial will be used to apply for FDA premarket approval for the vCLAS™ Cryoablation System [1] - The vCLAS™ Cryoablation System is commercially available in Europe and select other regions but is limited to investigational use in the U.S. [1] Recent Business Highlights - Adagio Medical closed a private placement on October 20, 2025, with gross proceeds of up to $50 million, led by healthcare-dedicated institutional investors [1]
Adagio Medical to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference